A novel approach to glaucoma treatment
Previously, the treatment algorithm for glaucoma relied on medical therapy at one end of the spectrum through to invasive procedures such as trabeculectomy at the other. Now, through close collaboration with teaching institutions, researchers and ophthalmic physicians, Nova Eye Medical is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
On 30 June 2020, the Company completed the divestment of the Ellex Lasers & Ultrasound business to Lumibird Group SA. Today, Nova Eye Medical has a unique opportunity to leverage its platform technologies to build a comprehensive portfolio of novel glaucoma treatment technologies and devices. It also has an opportunity to advance the commercialization of the 2RT™ project.
Latest ASX Announcements
See allCeasing to be a substantial holder
ASX Announcement General iTrack Molteno3 AlphaRET
20 Mar, 2024
Change in substantial shareholding from AEF
ASX Announcement General iTrack Molteno3 AlphaRET
20 Mar, 2024
Change of Director's Interest Notice VP
ASX Announcement General iTrack Molteno3 AlphaRET
19 Mar, 2024
Quick Links
Send an enquiry
For investor enquires please contact:
Mark Flynn
Nova Eye Medical Limited
W +61 416 068 733
mflynn@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More